Neurochemical Changes in Brain After Fetal Exposure to Fluoxetine, a Serotonin Reuptake Inhibitor (SRI) in Rodents

(E-pub Ahead of Print)

Author(s): Mona Awad Alonazi, Amina El Gezeery, Afaf el-Ansary, Ramesa Shafi Bhat*

Journal Name: Current Proteomics

Become EABM
Become Reviewer

Abstract:

Background: In utero exposure to Selective serotonin reuptake inhibitors (SSRI) is considered as a risk factor for many neurodevelopmental diseases.

Objective: The aim of this study was to investigate whether prenatal SSRI exposure changes newborn brain chemistry.

Method: An animal based study was designed in which utero SSRI exposed rat’s pups were compared to one without drug exposure. Neurochemical changes of the infants were assessed after 2 days of birth by estimating the levels of inflammatory cytokines, neurotransmitters and caspases in the brain exposed to SSRI at prenatal stage and compared to normal unexposed newborn.

Results: Our results showed significant neurochemical changes in SSRI-exposed newborns. A significant decrease in dopamine, and serotonin levels; with a remarkable decrease in noradrenaline in addition to remarkable increase of IFN-γ and caspase-3 levels was observed in the brain tissues of prenatal exposed SSRIs rat pups.

Conclusion: The results suggest that prenatal SSRI treatment may affect brain development of newborn hence should be used warily during gestation period.

Keywords: Depression, neurotransmitters, pro-inflammatory cytokines, caspases, brain

Rights & PermissionsPrintExport Cite as

Article Details

(E-pub Ahead of Print)
DOI: 10.2174/1570164617999201116154235
Price: $95